We talked to Thomas Hartman, president and chief executive officer (CEO) of the International Society of Pharmaceutical Engineering (ISPE), who underlines that no industry was prepared for the meteoric rise of AI in the past year: “Now, as AI fatigue begins to set in and there’s less of a race to implement AI in various processes, companies will have more time to take a step back and properly evaluate their technology and resources.”
We talked to Thomas Hartman, president and chief executive officer (CEO) of the International Society of Pharmaceutical Engineering (ISPE), who underlines that no industry was prepared for the meteoric rise of AI in the past year: “Now, as AI fatigue begins to set in and there’s less of a race to implement AI in various processes, companies will have more time to take a step back and properly evaluate their technology and resources.” As a result, companies will rely more on special interest groups and consultants with expertise in AI to provide guidance on best practices regarding generative AI implementation and the regulatory landscape.